Vote and Deadlines
- Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory (C28-P3)
- Performance Metrics for Continuous Interstitial Glucose Monitoring (POCT5-P)
CLSI submits the following for vote as a candidate-for-advancement consensus documents. The documents and ballots are available to delegates and alternates of Active and Associate Active member organizations through CLSI Forums.
Second Notice
C28-P3—Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Proposed Guideline—Third Edition
This document provides guidance for determining reference values and reference intervals for quantitative clinical laboratory tests. The deadline for the completed ballot for C28-P3 to be received at the CLSI offices is 26 May 2008.
POCT5-P—Performance Metrics for Continuous Interstitial Glucose Monitoring; Proposed
Guideline
This document provides consensus guidelines for health care professionals, IVD and medical device manufacturers, and regulatory agencies on how continuous glucose monitor (CGM) data should be; 1) presented; 2) compared between devices; and 3) compared between measurement technologies. The deadline for the completed ballot for POCT5-P to be received at the CLSI offices is 26 May 2008.
Under our Administrative Procedures, a CLSI document approved by the area committee at the first level of the consensus process is submitted to delegates as a “candidate-for-advancement” consensus document. This begins the voting and approval period by the delegates.
As a delegate, your vote is to affirm (or reject) the document for advancement as a CLSI document. Please send your completed ballot to the CLSI offices by the above deadline.
In the consensus process, comments are invited at each publication stage. In each edition, the responsible committee includes a summary of comments on the prior edition and its responses to them. Any comments received on a candidate-for-advancement consensus document as a result of delegate voting and consensus review will be addressed by the committee during the document’s advancement.
Find out more about Active and Associate Active membership.
[
return to top ]
|